Table 2. Baseline characteristics of the study population.
| Mean (SD or percentage) | Experimental | Control | Total | p-value |
|---|---|---|---|---|
| Number (% of total) | 10 (67%) | 5 (33%) | 15 | - |
| Male (% of the group) | 6 (60%) | 2 (40%) | 8 (53%) | 0.46 |
| Age (yr) | 69.8 (4.5) | 71.0(11.7) | 70.2 (7.3) | 0.78 |
| Height (cm) | 164.6 (10.1) | 163.6 (13.5) | 164.3 (10.9) | 0.87 |
| BMI (kg/m2) | 27.5 (4.1) | 28.1 (6.5) | 27.5 (6.5) | 0.85 |
| Disease duration (yr) | 6.2 (5.9) | 5.2 (4.7) | 5.9 (5.3) | 0.75 |
| Total LEDD | 614 (381) | 324 (295) | 517 (380) | 0.17 |
| Dopamine agonist LEDD | 54 (102) | 60 (66) | 56 (90) | 0.72 |
| H&Y stage | 3.0 (1.0) | 2.9 (0.7) | 2.9 (0.9) | 0.92 |
| UPDRS I | 5.3 (3.5) | 3.3 (2.4) | 4.6 (3.2) | 0.28 |
| UPDRS II | 18 (9.7) | 17 (5.7) | 17.7 (8.4) | 0.84 |
| UPDRS III | 35.1 (15.3) | 34.2 (12.3) | 34.8 (13.9) | 0.91 |
| MMSE | 24.9 (6.7) | 27.2 (1.1) | 25.7 (5.6) | 0.47 |
LEDD = regular levodopa dose x 1 + levodopa continuous release dose x 0.75 + ([regular levodopa dose + continuous release levodopa dose x 0.75] x 0.25 if taking tolcapone or entacapone) + pramipexole dose x 67 + ropinirole dose x 20 + rotigotine x 30 + pergolide dose x 100 + bromocriptine dose x 10 + cabergoline dose x 50 + amantadine dose x 0.5 + selegiline dose x 10 + resagiline dose x 100. H&Y = Hoehn and Yahr; UPDRS = Unified Parkinson's Disease Rating Scale; MMSE = Mini-Mental State Examination. An independent-samples t-test (or Mann–Whitney U test for non-parametric samples) was used for determining differences between groups except for participant’s gender, in which, a Fisher’s exact test was used.